Telephone sharing button Contact Us linkedin sharing button LinkedIn mailbox sharing button
arrow_left sharing button
arrow_right sharing button


WuXi Vaccines Wins the “Best Vaccine CMO Award of the Year” at the Asia Pacific Vaccine Excellence Awards 2022
Nov. 15, 2022
WuXi Vaccines Wins the “Best Vaccine CMO Award of the Year” at the Asia Pacific Vaccine Excellence Awards 2022

SHANGHAI, Nov. 9, 2022 – WuXi Vaccines, a global leading vaccines Contract Development and Manufacturing Organization (CDMO), received the ‘Best Vaccine CMO of the Year” at Asia-Pacific Vaccine Excellence Awards (AVEA) 2022.
AVEA 2022 recognises the outstanding achievements of vaccine & supply chain experts, organisations, and the newest technologies in Asia. The award was held in conjunction with the 4th Annual Vaccines World Asia Congress 2022 on November 9-10 in Singapore, attracting representatives across Asia’s top vaccine and supply chain organisations.


Award Wining Picture


WuXi Vaccines stood out among the five nominees with its integrated global CDMO Platform for vaccine development and manufacturing. During the pandemic, the company enabled a Global Top 10 pharma partner to achieve WHO Emergency Use Listing (EUL) in record speed of 9 months. Through this partnership, WuXi Vaccines delivered more than 500 million doses of our partner’s COVID-19 adenovirus vector vaccine, more than any other supplier, helping people fight COVID-19 in more than 180 countries.

Mr. Jian Dong, CEO of WuXi Vaccines, said, “We are honoured to receive this award. It is a true testimony to WuXi Vaccines’ end-to-end solution that enables our partners to bring more vaccine products to the market, more efficiently, to advance and benefit global health initiatives.”

About WuXi Vaccines
WuXi Vaccines focuses on vaccine discovery, development, and manufacturing. As a global leading CDMO, it provides world-class integrated development and manufacturing platforms to expedite partners’ vaccines to clinical stage and the market. Regardless of the vaccine modality (i.e., protein, virus, VLP, DNA, mRNA/RNA), WuXi Vaccines leverages its technical expertise, broad regulatory knowledge, premium quality system, advanced CMC development capabilities, multiple production platforms (mammalian, microbial, and viral), and extensive GMP manufacturing capacities to provide an end-to-end service – from vaccine discovery and development to large-scale commercial production and distribution. The company can enable any global partner to deliver critical vaccines anywhere in the world.
For more information about WuXi Vaccines, please visit:



You are leaving WuXi Biologics Website, after which our Privacy Notice will not apply. Please keep it in mind the protection of your privacy. Are you willing to proceed?